Các yếu tố thiết yếu trong điều trị chống đông trong thẩm phân máu

10.1126/science.145.3638.1310

10.1038/202498a0

10.1055/s-0037-1615947

10.1161/01.ATV.0000193624.28251.83

Rapaport SI, 1995, The tissue factor pathway, How it has become a “prima ballerina.”, 74, 7

10.1046/j.1523-1755.2001.00009.x

Noris M, 1999, Uremic bleeding, Closing the circle after 30 years of controversies?, 94, 2569

10.1053/ajkd.2002.32774

10.1016/S0272-6386(03)00860-6

10.1016/0272-6386(95)90655-X

10.1016/S0049-3848(03)00241-X

10.1177/107602960200800308

10.1038/sj.thj.6200072

10.1046/j.1523-1755.2002.00627.x

10.1177/107602960300900107

Vaziri ND, 1994, Blood coagulation, fibrinolytic, and inhibitory proteins in end‐stage renal disease, Effect of hemodialysis, 23, 828

Faioni EM, 1991, Low levels of the anticoagulant activity of protein C in patients with chronic renal insufficiency, An inhibitor of protein C is present in uremic plasma, 66, 420

Ambühl PM, 1997, Plasma hypercoagulability in hemodialysis patients, Impact of dialysis and anticoagulation, 12, 2355

10.1007/978-1-4020-2275-3_11

10.1016/S0142-9612(03)00380-6

10.1016/0140-6736(90)90815-M

10.1038/ki.1994.299

10.1046/j.1525-1594.1999.06271.x

Gawaz MP, 1999, Platelet‐leukocyte aggregates during hemodialysis, Effect of membrane type, 23, 29

10.1067/mlc.2001.114677

Basmadjian D, 1997, Coagulation on biomaterials in flowing blood, Some theoretical considerations, 18, 1511

10.1111/hdi.2001.5.1.74

Fischer KG., 2003, Heparin‐Induced Thrombocytopenia, 509

2002, European best practice guidelines for hemodialysis (part 1), Nephrol Dial Transplant, 17, 63

10.1159/000190134

10.1093/ndt/gfh203

10.1016/S0002-9343(96)00258-6

Magnani HN, 2006, Heparin‐induced thrombocytopenia (HIT), A report of 1,478 clinical outcomes of patients treated with danaparoid (Orgaran) from 1982 to mid-2004, 95, 967

10.1378/chest.115.6.1616

10.1055/s-2002-35288

Kern H, 1999, Bleeding after intermittent or continuous r‐hirudin during CVVH, Intens Care Med, 25, 1311, 10.1007/s001340051064

Vanholder RC, 1997, Pharmacokinetics of recombinant hirudin in hemodialyzed end‐stage renal failure patients, Thromb Haemost, 77, 650, 10.1055/s-0038-1656028

10.1046/j.1523-1755.56.s72.2.x

Bauersachs RM, 1999, Treatment of hirudin overdosage in a patient with chronic renal failure, Thromb Haemost, 81, 323, 10.1055/s-0037-1614470

Fischer KG, 2000, Treatment of hirudin overdose with hemofiltration, Blood Purif, 18, 80

Eichler P, 2000, Antihirudin antibodies in patients with heparin‐induced thrombocytopenia treated with lepirudin, Incidence, effects on aPTT, and clinical relevance, 96, 2373

10.1046/j.1365-2141.1999.01532.x

Huhle G, 2001, Anti‐r‐hirudin antibodies reveal clinical relevance through direct functional inactivation of r‐hirudin or prolongation of r‐hirudin's plasma half‐life, Thromb Haemost, 85, 936, 10.1055/s-0037-1615773

Fischer KG, 2003, Anti‐hirudin antibodies alter pharmacokinetics and pharmacodynamics of recombinant hirudin, Thromb Haemost, 89, 973, 10.1055/s-0037-1613398

10.1055/s-2002-35282

Swan SK, 2000, The pharmacokinetics and pharmacodynamics of argatroban, Effects of age, gender, and hepatic or renal dysfunction, 20, 318

10.1345/aph.1G033

10.1111/j.1523-1755.2004.66022.x

10.1345/aph.1E480

10.1007/s11239-006-9019-2

10.1345/aph.1D163

10.1056/NEJM200103013440901

Flanigan MJ, 1987, Reducing the hemorrhagic complications of hemodialysis, A controlled comparison of low-dose heparin and citrate anticoagulation, 9, 147

Böhler J, 1996, Reduction of granulocyte activation during hemodialysis with regional citrate anticoagulation—dissociation of complement activation and neutropenia from neutrophil degranulation, J Am Soc Nephrol, 7, 234, 10.1681/ASN.V72234

10.1046/j.1523-1755.1999.00671.x

10.1053/ajkd.2001.28584